List of Next-Gen Sequencing Companies in California - 61

Abterra Biosciences is reimagining antibody discovery and sequencing by harnessing the latest next-generation sequencing, mass spec, machine learning. Abterra Biosciences is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing.

AcelaBio, wholly owned by The Alimentiv Health Trust, was incorporated in 2020 and aims to meet the growing clinical research demand for quality and efficiency in laboratory service. Our state-of-the-art facility, located in San Diego, California, is built on deep expertise in clinical and precision medicine research and our scientific and operational experts are dedicated to delivering reliable, high-quality data.

Aegea Biotechnologies, Inc. is a technology company that is developing a series of reagents, research kits and in-vitro diagnostic (IVD) products for molecular analysis based on novel, patented and proprietary nucleic acid chemistries and methodologies.

Alida Biosciences is an early-stage, VC backed startup in San Diego focused on developing novel genomic analysis tools. The company’s technology will advance the understanding of RNA biology and provide actionable information for improving human health.

Apton is a California-based biotechnology company that manufactures and supplies single-molecule detection and sequencing imaging systems for clinical applications.

Axbio is a semiconductor-biotechnology company, developing cutting-edge technologies including nanopore sequencing, Bio-CMOS chips, and electrochemical sensors. Its sequencing and molecular diagnostics products are suitable for academia and industry users, serving large research laboratories as well as small clinics.

BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. Our mission is to enable scientists to eliminate disease and suffering through novel application of computational technologies and translating these findings directly and rapidly to clinical use. From its inception in 1997, BioDiscovery has been an innovative leader in the microarray informatics field having introduced the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. Our employees are excited about solving difficult problems and enabling scientist to make significant scientific breakthroughs. Our passion to make a difference has further extended the company’s reach into creating the most comprehensive enterprise-wide system for clinical applications enabling research findings to make direct impact on patient care. BioDiscovery is an equal opportunity employer with great benefits and a friendly, high-energy atmosphere. The company is headquartered in sunny Southern California near the Los Angeles International Airport (LAX) and has European headquarters in Cambridge, UK. We are always looking for talented individuals, eager to make a real difference, to join our company.

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research. Bionano also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through our Bionano Laboratories business, wey also offer OGM-based diagnostic testing services.

Biostate.AI is a startup founded in 2023 with the mission of developing generative AI for predictive omics analytics in the healthcare sector. They offer services such as RNA sequencing, DNA sequencing, image sequencing, image data analysis, and more. The company aims to lower costs and increase the utility of RNA sequencing for research and drug discovery.

Cantata Bio is enabling researchers and clinicians to solve tomorrow’s most challenging scientific problems through novel, multiomic approaches that unlock access to genomic and metagenomic information at unprecedented levels. Combining propriety technologies with platform solutions, services, and cutting-edge bioinformatics and software, our unique approaches are solving complex problems, including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, haplotype phasing, metagenomics, and microbiome analysis. Our customers are positively impacting the fields of epigenetics, developmental biology, cancer research, evolutionary biology, infectious disease, and more. Cantata Bio is based in Scotts Valley, California and Cambridge, Massachusetts. For more information on Cantata Bio, its technology, and offerings, visit www.cantatabio.com.

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/

Celemics is a Next Generation Sequencing (NGS) full solution provider based on target enrichment technology. We confidently offer custom target enrichment panels and high-quality pre-set panels, covering fields such as Inherited Diseases, Oncology, Immunology, and Pathogen Diagnostics. With 13 years of experience, we will provide the best solution for your Targeted Sequencing. [Products/Services] OncoRisk (Hereditary Cancer) | CancerScreen (Somatic Cancer) | Custom Target Enrichment Panel | Whole Exome Sequencing | Clinical Exome Sequencing | BRCA 1/2 | PharmacoScreen | Comprehensive Respiratory Virus | Agrigenomics

Cellecta provides HT loss-of-function genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA and CRISPR libraries, pooled library screening and analysis by NGS, targeted RNA-Seq for biomarker discovery, lentiviral reagents, and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.

ChromaCode is deploying a solution for mid-density, multiplexed analysis, high-definition PCR or HDPCR​.COVID-19: EUA (06/2020) for its HDPCR SARS-CoV-2 Real-Time PCR

We are an early-stage biotech startup based in Santa Cruz. We are a small, motivated, multi-disciplinary team innovating in NGS sequencing technologies and DNA assay design for applications in molecular diagnostics with focus on liquid biopsies, FFPE and ancient DNA Interested in beta testing our single-stranded approach to NGS library prep? Get in touch! www.claretbio.com/contact We are always looking to build our team with seasoned scientists who want to be on the ground-level of ground-breaking technology.

Clarity Genomics provides consulting services for microbiome-metabolome data insights in clinical research. Using our global network of specialists and regional cloud storage and computing, we provide expertise in collection and preparation of microbiome and metabolome samples, data processing and analysis. We work closely with our clients to offer biological insights that empower the development of new microbiome products and therapies. Partnerships with leading research institutions ensure that your project receives relevant information utilizing technologies and techniques on the forefront of innovation.

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

We are a well-funded stealth biotech company backed by some of the most experienced operators and investors in the biotech industry. Our co-founders are highly experienced researchers, clinicians, and entrepreneurs, on a mission to improve precision medicine with cutting-edge genomic technology.

Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including custom assay development, for biopharma and biotech companies and as a la carte services. Our areas of support include: - The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform - Multiomic characterization of small molecule and small oligonucleotide targets - Robust validation of on-target, and the identification of off-target, effects from small molecule and small oligonucleotide drugs - Deep profiling of RNA for groundbreaking discoveries in academic research Contact us today to discover how we can provide you with the insights needed for RNA success.

Edico Genome is a biotechnology company that specializes in developing cutting edge solutions for genomic sequencing analysis to provide unprecedented speed, scale, and accuracy.

Element Biosciences is a multi-disciplinary startup focused on developinggenetic analysis tools for the research and diagnostic markets.

Elim Biopharmaceuticals, Inc. is a leading life science service company for the biotech, pharmaceutical, and medical communities, offering a range of services from sequencing to synthesis, including drug quantification.

We are a skincare startup founded in 2018 in San Francisco. We combat the rise of skin conditions and sensitive skin by building a world in which beauty and science work together to produce optimal health. We develop clean, science-backed products that respect our skin's natural ecosystem. Discover our B2B microbiome tech platform @hellobiome. Our founder, Elsa Jungman, has a Ph.D. with strong expertise in dermatology, microbiome and clean beauty. She is a UCSF, L'Oréal and AOBiome alumna.

We are a biotechnology company offering end-to-end solutions in molecular diagnostic for oncology and hematology by providing hardware, reagents and software. Starting from automated nucleic acid extraction and culminating in genomic interpretation with its proprietary software embedded throughout entire workflow, EntroGen solutions are designed to be accurate, economic and scalable. EntroGen sells CRCdx®, a U.S. FDA-approved product.

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic’s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians with real-time information to guide treatment choices. For more information please contact us at info@epicsciences.com

Challenges with physical cell isolation limit adoption of single-cell sequencing. So we figured out how to prepare complete libraries within intact cells.

Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike. - Our Products & Services - Fulgent Genetics https://www.fulgentgenetics.com/ Fulgent Oncology https://fulgentoncology.com/ Fulgent BioPharma https://biopharma.fulgent.com/ Picture Genetics https://picturegenetics.com/ HelioLiver https://www.helioliver.com/ Fulgent is a CLIA-certified and CAP-accredited laboratory. _____________ NASDAQ: FLGT

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

INanoBio’s mission is to develop high-accuracy early stage disease diagnostics using transformative nano-biotechnology platforms and machine learning. Extract systems scale information from complex disease biology, identify and detect disease specific molecular biomarkers, signatures at prodromal or pre-symptomatic stages. We believe most diseases can be detected early, enabling early personalized therapeutic intervention to preempt full development of diseases, ushering in preemptive medicine.

Intelliseq provides state of the art solutions for next generation sequencing. A team of passionate and skilled bioinformaticians, geneticists and molecular biologists approaches next generation DNA sequencing challenges with creativity and flexibility.

The mission of the Department of Energy is to ensure America's security and prosperity by addressing its energy, environmental, and nuclear challenges through transformative science and technology solutions. Goal 1: Science and Energy — Advance foundational science, innovate energy technologies, and inform data driven policies that enhance U.S. economic growth and job creation, energy security, and environmental quality. Goal 2: Nuclear Security — Strengthen national security by maintaining and modernizing the nuclear stockpile and nuclear security infrastructure, reducing global nuclear threats, providing for nuclear propulsion, improving physical and cybersecurity, and strengthening key science, technology, and engineering capabilities Goal 3: Management and Performance — Position the Department of Energy to meet the challenges of the 21st century and the nation's Manhattan Project and Cold War legacy responsibilities by employing effective management and refining operational and support capabilities to pursue departmental missions

Jumpcode Genomics is changing the way scientists see their samples with our proprietary CRISPRclean® technology. Combining CRISPR-based technology and next-generation sequencing (NGS) they can now search for and find novel signals they previously couldn't. Our technology removes unwanted sequences, allowing researchers worldwide to extract greater insights. By increasing sensitivity and allowing access to a range of sample types, we're broadening the understanding of human biology in fields from research to clinical applications including infectious disease and oncology.

SVBio is now LIfecode, Inc. We are focused on the genetic basis of human disease. With an initial focus in oncology, Lifecode is committed to improving the lives of patients through molecular information that is concise, accurate and actionable. The long-term vision of Lifecode is to revolutionize the world of genomic medicine.

LifeMap Sciences offers a leading integrated biomedical knowledgebase for empowered life sciences research and precision medicine, and a powerful advertising products for research reagents. Our products are used by more than 5 million researchers from both academia and the biopharma industry. GeneCards (www.genecards.org) is a searchable, integrative database that provides comprehensive, user-friendly information on all annotated and predicted human genes. The knowledgebase automatically integrates gene-centric data from ~150 web sources, including genomic, transcriptomic, proteomic, genetic, clinical and functional information. MalaCards (www.malacards.org) is an integrated database of human maladies and their annotations, modelled on the architecture and richness of the popular GeneCards database of human genes. Today, it offers information about 22,060 disease entries, consolidated from 74 sources

Loop Genomics technology transforms short-read DNA sequencers into high-throughput, long-read, single-molecule DNA sequencing machines.

Machaon Diagnostics is a clinical reference laboratory and contract research organization (CRO), specializing in the diagnosis, treatment and monitoring of hemostatic and thrombotic conditions, complement-mediated disorders and rare genetic diseases. Machaon Diagnostics has a mission to save more lives with lab tests. Started as a collaboration of four laboratory scientists, we have rapidly grown into a dedicated group of clinicians, scientists, consultants and technologists. Collectively, the Machaon Diagnostics team brings over 400+ years of expertise to the field of laboratory testing. Our esoteric and routine testing menu applies to a wide variety of disorders and clinical trials and therefore draws attention from both a national and an international clientele. Our clients include community hospitals, university medical centers, clinics, commercial laboratories and research laboratories, as well as biotechnology, pharmaceutical and medical device companies. Machaon brings custom solutions to hospitals, laboratories and trial sponsors. Our primary goal is to provide quality testing (CAP/CLIA, GLP, GCP) at industry-leading speed.

Established in 1998, Molecular Cloning Laboratories (MCLAB) is a leader in providing genomic research consumables and services to the Life Sciences community. MCLAB provides cost-effective consumables and reagents, focusing on first generation as well as next-generation sequencing and DNA fragment analysis. We manufacture a large selection of molecular biology related products, including antibodies, biochemical reagents, cloning kits, enzymes, PCR kits, protein gels & solutions and more. With a team of over twenty experienced scientists and over six decades of experience, MCLAB is committed to offering first-rate services to researchers. We specialize in the field of genomics, with experts in DNA sequencing, fermentation, fragment analysis, molecular cloning, over-expression, protein purification, and protein synthesis. MCLAB has offices in China and distributors all around the world, including Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Germany, Hungary, Greece, India, Israel, Poland, New Zealand, Turkey, United Kingdom and Vietnam.

Monogram Biosciences, a LabCorp company, is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. Our molecular diagnostics and testing services enable Healthcare providers to optimize treatment regimens for their patients to lead to better outcomes and reduced costs by matching the underlying molecular elements of an individual patient's disease to the drug best able to affect those elements. Further, we work with pharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics more efficiently by providing enhanced patient selection and monitoring capabilities throughout the development process. We have developed HIV tests, or assays, to help make the complexities of antiretroviral therapy easier to manage. We have also developed oncology products to help accelerate the development of targeted cancer therapeutics.

Murrieta Genomics is dedicated to advancing the use of genomic sequencing in precision medicine, agriculture, forensics, veterinary and direct to consumer applications by offering entrepreneurs access to the specialized equipment, know-how and mentors that can transform research into commercial enterprise. We are a true incubator, offering dedicated bench space to fledgling companies at basically zero cost, helping them to define their business model and validate their science, and then investing in the companies that "graduate" the incubator. We are located in the 16,000 square foot Murrieta Innovation Center in Southern California, in close proximity to Los Angeles, San Diego and Orange County. We welcome inquiries from researchers, entrepreneurs, scientists, investors, and business professionals who share our passion for advancing science and sparking economic development.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise and experience with 45 NGS-related patents, as well as over 950 SCI articles with a total impact factor of more than 7970, including publications in first tiers journals such as Cell, Nature and Science. The UC Davis location of Novogene Corporation Inc. was opened in early 2016. We utilize Illumina platform to serve customers in North and South America, and we also offer PacBio and Nanopore services. Novogene Corporation Inc. is proud to have collaborated with scientists from the USA, Canada, Brazil, Colombia, Mexico, and so many more. We are excited to see this global collaboration and partnership growing.

At PacBio, we’re devoted to empowering you. Pioneering the future through biology takes vision. You have to look beyond the status quo to what’s possible. We know your vision can reveal the full potential of the genome, advance human health and the health of our planet. And that is why your vision and pursuit are at the very center of what our company does — our product design, our customer support model, our partnerships, and even our identity. We create the world’s most advanced sequencing systems to provide you the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our founders invented a new way to study the synthesis and regulation of DNA, RNA, and proteins. Driven by a desire to advance human health, we’re harnessing advances in biochemistry, optics, nanofabrication, and more. We are passionate about developing products that empower scientists to explore the full spectrum of genetic variation in any organism — from unraveling the mystery of rare diseases to improving the world’s food supply. With world-class service and support, we keep your research progressing so you can focus on finding answers. We encourage you to see the whole picture — and consider us the partner you trust to see it too.

At PacBio, we’re devoted to empowering you. Pioneering the future through biology takes vision. You have to look beyond the status quo to what’s possible. We know your vision can reveal the full potential of the genome, advance human health and the health of our planet. And that is why your vision and pursuit are at the very center of what our company does — our product design, our customer support model, our partnerships, and even our identity. We create the world’s most advanced sequencing systems to provide you the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our founders invented a new way to study the synthesis and regulation of DNA, RNA, and proteins. Driven by a desire to advance human health, we’re harnessing advances in biochemistry, optics, nanofabrication, and more. We are passionate about developing products that empower scientists to explore the full spectrum of genetic variation in any organism — from unraveling the mystery of rare diseases to improving the world’s food supply. With world-class service and support, we keep your research progressing so you can focus on finding answers. We encourage you to see the whole picture — and consider us the partner you trust to see it too.

Phalanx Biotech Group provides genomics research products and services worldwide to academic, pharmaceutical and biotech communities. We developed the OneArray® line of high-quality and affordable microarrays for expression profiling of whole genomes, microRNA, and custom targets. Our service specialists offer comprehensive services including sample preparation, expression analysis, and qPCR validation. In 2017, Phalanx is pleased to announce that it has added Next Generation Sequencing Services (NGS) and corresponding NGS Bioinformatics to its service offerings.

Disrupting research enzyme/protein production, we are the first to introduce a Taq Polymerase free from background DNA contamination. We are now proud to introduce our new RNA extraction free EF1 SARS-CoV-2 Detection Kit, CE marked for in vitro diagnostics! Find out how we plan to have the gold standard of testing available with results in less time it takes to explain your job to grandma!

Pleno Inc. is an early-stage San Diego startup company developing a multi-omic instrument platform to revolutionize biological target detection for clinical testing and biomedical research and enable a broad array of applications from screening and detection, to diagnostics, prognostics and beyond. We are driven and dedicated scientists, engineers and business professionals. We're developing an innovative and disruptive multi-omic instrument platform that's going to transform the insights from and application of biological information. We're in an exciting growth phase and are actively expanding our team. Join us to experience the energy and excitement of taking on the biggest challenges in biosciences and biotechnology to develop innovative solutions that will disrupt the industry. You'll have the support to flourish both professionally and personally, where your ideas are valued and your commitment and collaboration is key to our success.

Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.

Quantapore Inc. is developing a nanopore based nucleic acid sequencing technology thatutilizes an optical read out which results in lower cost and higher throughput compared to electrical data acquisition.

QuickBiology is a fully automated, high-throughput genomic center equipped with all major next generation sequencing. QB provides state-of-the-art genomics technologies, comprehensive services, specialized expertise enabling these services in a cost-effective and timely manner to serve basic science and translational/clinical research. QB’s service included, but not limited to, RNA sequencing, whole exome sequencing, whole genome sequencing, ATAC sequencing and single cell RNA sequencing.

RealSeq Biosciences’ core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction, targeted NGS tools, and cf-RNA analysis (liquid biopsy) that form the basis of the Company’s life science research programs and product development.

At Rondo Therapeutics we believe that our success as a company starts with building a culture based on teamwork, trust, career growth, and a sense of fun. If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture. Rondo Therapeutics is committed to advancing the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies. Our solution is to create a new class of bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti tumor response.

Serimmune is an immune intelligence company that provides a holistic view of immunity to identify environmental factors in disease and health. Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity.

Singular Genomics is driving innovation at the forefront of multiomics. Dedicated to supporting the scientific community, we focus on creating scientific advancements influenced by real-world feedback and solution-oriented development. As a publicly-traded life science technology company, we specialize in advanced next-generation sequencing (NGS) and multiomic technologies, developing products that empower researchers and clinicians. The G4 Sequencing Platform, our first commercially available product, is an innovative benchtop sequencer featuring a novel 4-color rapid sequencing-by-synthesis (SBS) chemistry and advanced engineering, providing single-day turnaround times for various applications. Our recently launched G4X Spatial Sequencer, which is an upgrade to the G4 Sequencing Platform, is designed to offer high throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues. We are committed to unlocking the potential of our core technologies to reshape the future of multiomics. We offer a dynamic, fast-paced, results-oriented environment where employees can make a significant impact. Innovation, continuous learning, multi-disciplinary collaboration, and diversity of thought are pillars of our culture.

info@smlgenetree.com | www.smlgenetree.com | SML Genetree is recognized as a premier partner in developing technology and on-time delivery, providing both basic research of molecular biology and applied research in molecular diagnosis. SML Genetree is an affiliate of Samkwang Medical Laboratories (SML), one of the largest diagnostic commercial labs in South Korea in 1985.

Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a Takara Bio company, develops, manufactures, and distributes a wide range of life science reagents under the Takara®, Cellartis®, and Clontech® brands. Our products support applications including stem cell research; NGS; gene discovery, regulation, and function studies; protein expression and purification; RNAi and gene editing; and plant and food research.

Trace Genomics is a pioneer in the use of hi-definition genomics to activate the hidden insights in soil for healthier soils and a healthier planet. Through innovation in genomics, soil science and machine learning, Trace Genomics creates a pathway to deliver targeted database insights and actions at cost-speed-scale-accuracy for partners who are advancing modern farming solutions for a net-zero food production system. Where most companies deliver a partial picture, we provide a comprehensive and precise understanding of the soil’s composition—analyzing the soil’s biology, physical properties and chemistry. Trace Genomics has won several awards, including being selected as a 2020 Technology Pioneer by the World Economic Forum, Winner of FoodShot Global’s Innovating Soil 3.0 Challenge, Forbes Top 25 Most Innovative AgTech, THRIVE Top 50 AgTech, 2022 Global Cleantech top 100 start-ups and many more.

Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, industrial chemicals and data storage, scientists use our synthetic genes, oligo pools, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise unavailable. Our technology overcomes inefficiencies and enables cost-effective, rapid, precise, high-throughput DNA synthesis and sequencing. We offer both the quality and quantity researchers need now to rapidly realize opportunities ahead. Twitter @TwistBioscience Facebook facebook.com/TwistBioscience YouTube youtube.com/TwistBioscience #WeMakeDNA

Verogen is a California-based company that develops and distributes next-generation gene sequencing panels and genetic code analyzing products for the healthcare sector.

Zafrens is a therapeutics company pioneering an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function. The company’s mission is to unlock the full story of every cell to accelerate drug discovery.

Since its inception in 1994, Zymo Research has been proudly serving the scientific community by providing innovative, reliable, and high quality research tools at affordable prices. Our vision..."The Beauty of Science is to Make Things Simple"​ is now truer than ever. Whether it's epigenetics, DNA, RNA, E. coli, or yeast based research, our philosophy remains the same: To provide the highest quality products in the industry while ensuring they are both simple to use and reliable in their performance. Zymo Research is historically recognized for its innovation of high quality nucleic acid purification technologies. Under the branding DNA Purification Made Simple™ and RNA Purification Made Simple™, our technologies are pushing the limits of what is possible with nucleic acid isolation. As The Epigenetics Company™, Zymo Research has also received much attention for its rapidly expanding portfolio of epigenetics products and services. It is our objective to develop and provide the most comprehensive set of tools for DNA, RNA, and epigenetic research and analysis available today. Thousands of peer-reviewed scientific publications from researchers around the world feature our technologies. Through innovation, our scientists have made streamlined DNA methylation detection possible, pioneered the micro-elution column for DNA and RNA purification, developed the simplest and the most sophisticated methods for high-quality plasmid DNA purification, and patented the first RNA purification directly from Trizol without phase separation among many other leading technologies in the industry. At Zymo Research, we are committed to quality and guarantee that all of our products and service will meet and exceed your expectations. We pledge to be honest and responsible for everything we do with you. We will treat you as we would like to be treated. Together, we will build a brighter future.